Focus on Cell-Based Diagnostics and Therapy The Thematic Issue summarizes the current progress in the development of novel approaches to diagnostics and therapy with special focus on cell-based technologies. Identification of novel biomarkers and biologically active molecules is a rapidly developing and highly competitive field.
We help transform market performance by forging professional partnerships between Key Opinion Leaders KOL and our clients. Our KOL development strategy is designed to facilitate relationship-building that is productive for both sides.
Identification and engagement of appropriate key opinion leaders are critical to the success of a product or brand.
Today physician prescribing decisions are guided by multiple factors which are on the rise. However, key opinion leaders continue to be the consistent factor that influences physicians at the regional, national and global levels.
D2L has come up with innovative methodologies to enable the healthcare and pharma community to connect with the opinion and thought leaders in the best KOL industry. At D2L, we provide the strategic market insight you require for collaborating with top KOLs that can influence your target markets.
Our innovative key opinion leader mapping strategy involves the use of latest methodologies, analytics, and human expertise to recognize high prescribes in any therapeutic segment.
We bring to the table our repository of in-depth knowledge, processes, and data points that help clients to achieve accurate results and optimize engagement with key stakeholders.
With our highly knowledgeable, experienced, and talented group of research experts, we remain committed to deliver the most comprehensive KOL engagement services spreading across various disciplines, specialties and therapeutic areas. We have vast expertise in the industries we serve, which involves the medical communication companies, healthcare, and pharma sectors.
It is our quest to provide unparalleled service to clients and key stakeholders that helps us to meet and exceed expectations time and again.
Armed with a proficient, enthusiastic and dedicated team of more than Employees, the company remains strongly adhered to quality, ethics, science and service to Health care Industries. Board of Directors Dr. Sashi Kiran Kode has established himself in various fields and specially the one when it is related to the medical one, Dr.
Kiran brought his commitment and gifts as doctor and trainer to patients suffering from a wide range of maladies.
He has achieved a confluence of medicine with the pharmaceutical industry, boosting both, and preventing duplication of research and the reinvention of the wheel.
This interface between the two fields will make medicine more effective and the pharmaceutical industry more purposive. Kiran began his career as an investigator in several research studies with a focus on India and its problems in offering high-quality medical treatment.
Already with a Masters in Surgery, he had a revolutionary change in his life with a British Fellowship as he became deeply interested in head and neck cancers as well as thyroid disorders among other life-altering areas such as spinal injuries.
Ever the researcher at the cutting edge of medicine, Dr. Kiran founded D2L in The company has now become a pioneer of research in medicine reaping rich rewards in the development of new drugs.
With not just the quality of a great researcher, he is a corporate strategy and development specialist with operational excellence. He has the power of effective leadership, possess high orientation and people skills.
His work life has contributed in developing training modules for clinical operations at hospitals.Industry is the production of goods or related services within an economy.
The major source of revenue of a group or company is the indicator of its relevant industry. When a large group has multiple sources of revenue generation, it is considered to be working in different industries.
This online course is designed for every person who is involved in a metrics program, including operators and quality control personnel who contribute to generating the raw data, through to those involved in collecting, submitting and, most importantly, analyzing the data, drawing conclusions, and taking relevant and necessary actions to implement continual improvement projects.
Companies across the healthcare industry recognize they need to deliver greater value—higher quality of care at a lower cost. To some extent, this pressure comes from changing government policies. 10 Critical success factors for pharma lifecycle management Click here if you wish to regularly receive articles, interviews, quizzes and exercises from our expert faculty through our Newsletter.
By Dr. Neal Hansen, expert-trainer of the Late Stage Pharma Lifecycle Management course. SCORES 24 Industry Benchmarks B Introduction Industry Analysis Merck & Co. Sanofi Key Success Factors Recommendations Conclusion Above is a table representing Merck & Co.
and Sanofi comparing notable ratios against the entire pharmaceutical manufacturing industry. FIP is the global federation representing four million pharmacists and pharmaceutical scientists worldwide.
Read more about us».